to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Advance directives are commonly used for end-of-life medical decisions, but through consumer research, MyDirectives' co-founder Jeff Zucker has learned they can be used to instantly make life better for all users, and not just those near death.
A well-established business model is important for any startup, but it becomes even more vital for startups developing platform technology. IRISense CEO Brent Cousino said his company had multiple value propositions for his innovation that have provided different expansion paths of success.
See who made this week's list
At a Life Science Ventures Summit hosted by the Kauffman Foundation, Huffington Post writer Jennifer Hill led a discussion focused on the players in entrepreneurship. The presentation opened with experienced entrepreneurs giving their thoughts on the idea of team building. (00:00-01:19)
Ronald Lindsay, CEO of Zebra Biologics Inc., thinks changes in the biotech industry will lead to a trend of success for biotech companies. His company’s technology can be used as a platform to discover and develop bio-superior antibody therapeutics and complex drug targets. Zebra has just pulled in $9 million in its first investing round, and Lindsay thinks one of the biggest changes for the future of biotech is the availability of venture funding.
See who made this week's 6 to follow
A Life Science Ventures Summit hosted by the Kauffman Foundation provided advice on funding strategies for diagnostic startups (0:30:25-0:35:38). Diana Kander of Kander Rigby led a panel with Una Ryan, Tito Serafini, Risa Stack, Zen Chu and Jill Carroll.
At the core of any startup company is the idea. The idea is the true value of a company, according to LIM Innovations CEO and co-founder Andrew Pedtke, and he says protecting that idea should be a main priority.
See who made this week's list.
Paul Yock of Stanford's Biodesign and Jay Watkins of De Novo Ventures led a discussion with Marie Johnson, Darin Buxbaum, Brian Fahey and Peggy McLaughlin on the topic of clinical and regulatory strategy at a recent Life Science Ventures Summit hosted by the Kauffman Foundation (0:25:21-0:33:52).
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.